Cleveland BioLabs has submitted a response to the request for proposal issued by the Department of Defense (DoD) for the FDA approval/licensure and delivery of a medical radiation countermeasure.
DoD's request for proposal described a countermeasure as one that would be administered following exposure to ionizing radiation that will decrease incapacity and prolong survival by treating the gastrointestinal sub-syndrome of acute radiation syndrome, said Cleveland BioLabs.
Recently the Buffalo, N.Y.-based company received a patent covering the method of protecting humans from radiation using flagellin or its derivatives, including CBLB502. Michael Fonstein, PhD, CEO and president of Cleveland BioLabs said, "we believe our radiation protection drug candidate, CBLB502, fits these and other listed criteria."
Cleveland BioLabs said it has received more than $32 million in development funding over the past two years from several federal agencies, including the DoD, the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services, and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health.